Bacillus calmette-guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer

European Urology

Volumn 60, Issue 1, 2011, Pages 32-36

  Herr, Harry W ^a,b   Dalbagni, Guido ^a   Donat, Sherri M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

BCG; Bladder cancer; Mainetenance

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TRANSURETHRAL RESECTION; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 79957950996     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.03.051     Document Type: Article

References (23)

1. A. Morales, D. Eidinger, and A.W. Bruce Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors J Urol 116 1976 180 184
2. D.L. Lamm, D.E. Thor, and S.C. Harris Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer J Urol 124 1980 38 43
3. H.W. Herr, C.M. Pinsky, and W.F. Whitmore Jr. Effect of intravesical bacillus Calmette-Guérin on carcinoma in situ of the bladder Cancer 51 1983 1323 1326 (Pubitemid 13161114)
4. D.L. Lamm, B.A. Blumenstein, and E.D. Crawford A randomized trial of intravesical doxorubicin and immunotherapy with BCG for transitional cell carcinoma of the bladder New Engl J Med 325 1991 1205 1209
5. P.U. Malmstrom, H. Wijkstrom, and C. Lundholm 5-year follow-up of a randomized prospective study comparing mitomycin C and BCG in patients with superficial bladder carcinoma J Urol 161 1999 1124 1127 (Pubitemid 29426100)
6. M. Babjuk, W. Oosterlinck, and R. Syvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303 314
7. M.C. Hall, S.S. Chang, and G. Dalbagni Guideline for the management of nonmuscle invasive bladder cancer (stages Ta,T1 and Tis): 2007 update J Urol 178 2007 2314 2330 (Pubitemid 350080987)
8. J.E. Montie, P.E. Clark, and M.A. Eisenberger National Comprehensive Cancer Network. Bladder cancer J Natl Compr Canc Netw 7 2009 8 39
9. D.K. Lamm, B.A. Blunemstein, and J.D. Crissman Maintenance BCG immunotherapy for recurrent TA,T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124 1129 (Pubitemid 30169376)
10. R. Sylvester, A. Van der Meijden, and D. Lamm Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
11. H.W. Herr, V.P. Laudone, and R.A. Badalament Bacillus Calmette-Guérin therapy alters progression of superficial bladder cancer J Clin Oncol 6 1988 1450 1455 (Pubitemid 19089034)
12. H.W. Herr, D.M. Schwalb, and Z.-F. Zhang Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial J Clin Oncol 13 1995 1404 1408
13. R.A. Badalament, H.W. Herr, and G.Y. Wong A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette- Guérin therapy of superficial bladder cancer J Clin Oncol 5 1987 441 449 (Pubitemid 17045468)
14. H.W. Herr Is maintenance bacillus Calmette-Guérin therapy necessary? Eur Urol 54 2008 971 973
15. H. Koga, S. Ozono, and T. Tsushima Maintenance intravesical BCG instillation for Ta,T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo strain study group Int J Urol 17 2010 759 766
16. Hinotsu S, Akaza H, Naito S, et al. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumor for non-muscle-invasive bladder cancer. BJU Int. In press. DOI:10.1111/j.1464-410X. 2010.09891.x.
17. A.Z. Weizer, C. Tallman, and J.S. Montgomery Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer World J Urol 29 2011 59 71
18. A.P.M. van der Meijden, R.J. Sylvester, and W. Oosterlinck Maintenance bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial Eur Urol 44 2003 429 434 (Pubitemid 37185667)
19. P.-U. Malmström, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
20. P. Gontero, A. Bohle, and P.-U. Malmstrom The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer Eur Urol 57 2010 410 429
21. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
22. W. Oosterlinck, Z. Kirkali, and R. Sylvester Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC phase 2 trial Eur Urol 59 2011 438 446
23. K.G. Nepple, A.J. Lightfoot, and H.M. Rosevear Bacillus Calmette-Guérin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer J Urol 184 2010 1915 1919